Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The completion of the Biochemistry building reached a symbolic milestone in early October, with the unification of the building’s two phases

hole in the plasterboard resulting from the breakthrough

A short ceremony marked the occasion of breaking through the temporary wall between the two phases.

Senior scientists and project leaders were present to witness a hole being knocked through a thin plasterboard wall that had protected the final phase of the construction works. They marked the two phases of the building being brought together by passing a model of the molecular structure of penicillin through the opening – much of the work to enable the antibiotic to be used on a large scale was undertaken by Oxford researchers. The hole is now being enlarged to unify the laboratory and desk-based research facilities.

The full story is available on the University of Oxford's Estates Services website

Find out more about the completion of the Biochemistry Building

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.